REGULATION OF BILIARY EXCRETION OF XENOBIOTICS BY MRP2
REGULATION OF BILIARY EXCRETION OF XENOBIOTICS BY MRP2
批准号:
6518139
负责人:
CURTIS D KLAASSEN
金额:
$30.0万
依托单位国家:
美国
项目类别:
财政年份:
2000
资助国家:
美国
项目状态:
已结题
起止时间:
2000-08-01 至 2005-06-30
关键词:
DNA footprinting biliary tract biological transport cytochrome P450 detoxification drug metabolism enzyme activity excretion fluorescence microscopy gel mobility shift assay high performance liquid chromatography laboratory rat molecular cloning multidrug resistance nuclear runoff assay phosphorylation protein kinase protein structure function receptor expression second messengers tissue /cell culture toxin metabolism western blottings
中文摘要
描述(改编自申请人摘要):生物转化和
异生物质、药物和化学品的解毒本质上是
这取决于生物体排泄这些化合物的能力。排泄
系统可被化疗剂上调,
在许多癌症中观察到多药耐药性。化疗诱导药物
耐药性是由于运输化学物质的蛋白质的过度表达
从癌细胞中分离出来这些蛋白质包括P-糖蛋白和
多药耐药蛋白(Mrp),由多种药物编码,
耐药基因(MDR)和mrp基因。在正常肝脏中,
肝小管膜转运蛋白的定位
实质细胞对于输出/排泄
化学物质进入胆汁。mrp基因家族的一个成员,Mrp 2(以前的cMOAT),
是一种ATP依赖性小管转运蛋白,负责
排泄各种有机阴离子,包括谷胱甘肽,硫酸盐,
化学品和异生物质的葡糖苷酸缀合物。这些运输过程,
其中MRP 2是一个关键组成部分,现在被认为是“第三阶段”,
药物/化学肝脏代谢过程。这第三个人
生物转化阶段可以与阶段I和阶段II协调调节,
和II系统对化学刺激的反应是有趣的,
生物转化的所有三个阶段都是耦合的,
肝细胞代谢/化学品解毒的效率。这
实验室已经报道了化学物质增加肝胆的能力,
功能,我们假设这是内在相关的Mrp 2表达和
功能前两个目标将测试假设,这些观察
是由于III期代谢的改变,更具体地说是Mrp 2的改变
调控这个实验室发表了大量的研究成果
表明新生动物体内的化学物质毒性显著增加,
这是由于化学诱导的肝胆功能增强。目标3
应用程序将测试化学引起的成熟的假设,
新生儿肝胆功能是由于Mrp 2功能增强和/或
表情此外,该实验室报告说,化学-化学
相互作用可引起肝排泄载体的转变,
减少肝胆排泄和增加肝血管排泄。目标4
将检验这一假设,即肝脏排泄的这种转变是由于
Mrp 2在肝胆管中的化学诱导差异表达
膜和Mrp 3在窦膜上。最后一个目标测试了一个完全
药物代谢的新概念和胆汁中蛋白质的调控
排泄,也就是说,Mrp 2是由一个孤儿核受体,
胆甾烷X受体。阐明控制Mrp 2介导的
排泄药物将继续启发科学和医学
生物外源性物质运输过程的重要性,
创造安全和生物活性的药物,
运输缺陷和保护公众免受化学品接触。
英文摘要
DESCRIPTION ( Adapted from the applicant's abstract): Biotransformation and
detoxication of xenobiotics, pharmaceuticals, and chemicals is intrinsically
dependent on the organism's capacity to excrete these compounds. The excretory
systems can be upregulated by chemotherapeutic agents in the phenomenon of
multidrug resistance observed in many cancers. Chemotherapy-induced drug
resistance is due to the overexpression of proteins which transport chemicals
out of cancer cells. These proteins include P-glycoprotein and
multidrug-resistance proteins (Mrp) which are encoded by the multiple drug
resistance gene (MDR) and the mrp genes, respectively. In normal liver,
localization of transport proteins in the canalicular membrane of hepatic
parenchymal cells is physiologically important for export/excretion of
chemicals into bile. One member of the mrp gene family, Mrp2 (formerly cMOAT),
is an ATP-dependent canalicular transporter protein responsible for the
excretion of various organic anions, including glutathione, sulfate, and
glucuronide conjugates of chemicals and xenobiotics. These transport processes,
of which Mrp2 is a critical component, are now considered the "phase III"
process of drug/chemical hepatic metabolism. The possibility that this third
phase of biotransformation can be regulated in coordination with both phase I
and II systems in response to chemical stimuli is intriguing and would suggest
that all three phases of biotransformation are coupled to increase the
efficiency of hepatocellular metabolism/detoxication of chemicals. This
laboratory has reported on the ability of chemicals to increase hepatobiliary
function, which we postulate to be intrinsically related to Mrp2 expression and
function. The first two aims will test the hypothesis that these observations
are due to altered phase III metabolism, more specifically altered Mrp2
regulation. This laboratory has published an extensive amount of research
showing that marked increases in toxicity of chemicals in newborn animals occur
as a result of chemical-induced enhanced hepatobiliary function. Aim 3 of this
application will test the hypothesis that chemical-elicited maturation of
neonatal hepatobiliary function is due to enhancement of Mrp2 function and/or
expression. Further, this laboratory has reported that chemical-chemical
interactions can cause a transition shift in the vector of hepatic excretion to
decrease hepatobiliary excretion and increase hepatovascular excretion. Aim 4
will test the hypothesis that this transition in hepatic excretion occurs due
to the chemical-induced differential expression of Mrp2 on the hepatobiliary
membrane and Mrp3 on the sinusoidal membrane. The last Aim tests an entirely
new concept in drug metabolism and control of proteins involved in biliary
excretion, that is, that Mrp2 is regulated by an orphan nuclear receptor, the
pregnane X receptor. Elucidation of mechanisms that control Mrp2-mediated
excretion of drugs will continue to enlighten the scientific and medical
communities as to the importance of xenobiotic transport processes in relation
to creating safe and biologically active drugs that alleviate specific
transport deficiencies and protecting the public from chemical exposure.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
COBRE: U OF KANSAS MEDICAL CTR : CORE A: ADMINISTRATIVE CORE
-
批准号:7610767
-
项目类别:
-
资助金额:$38.82万
-
财政年份:2007
-
负责人:CURTIS D KLAASSEN
-
依托单位:
Nuclear Receptors in Liver Health and Disease
-
批准号:6963316
-
项目类别:
-
资助金额:$191.67万
-
财政年份:2006
-
负责人:CURTIS D KLAASSEN
-
依托单位:
COBRE: U OF KANSAS MEDICAL CTR : CORE A: ADMINISTRATIVE CORE
-
批准号:7382246
-
项目类别:
-
资助金额:$45.85万
-
财政年份:2006
-
负责人:CURTIS D KLAASSEN
-
依托单位:
Nuclear Receptors in Liver Health and Disease
-
批准号:7236612
-
项目类别:
-
资助金额:$202.6万
-
财政年份:2006
-
负责人:CURTIS D KLAASSEN
-
依托单位:
Coordinate Regulation of Uptake and Efflux Transporters
-
批准号:7030713
-
项目类别:
-
资助金额:$34.91万
-
财政年份:2006
-
负责人:CURTIS D KLAASSEN
-
依托单位:
Coordinate Regulation of Uptake and Efflux Transporters
-
批准号:7168010
-
项目类别:
-
资助金额:$33.9万
-
财政年份:2006
-
负责人:CURTIS D KLAASSEN
-
依托单位:
REGULATION OF BILIARY EXCRETION OF XENOBIOTICS BY MRP2
-
批准号:6607711
-
项目类别:
-
资助金额:$30.0万
-
财政年份:2000
-
负责人:CURTIS D KLAASSEN
-
依托单位:
Regulation of Hepatic Uptake of Drugs and Xenobiotics
-
批准号:7030423
-
项目类别:
-
资助金额:$36.75万
-
财政年份:2000
-
负责人:CURTIS D KLAASSEN
-
依托单位:
Regulation of Hepatic Excretion of Xenobiotics by Mrps
-
批准号:7093310
-
项目类别:
-
资助金额:$34.91万
-
财政年份:2000
-
负责人:CURTIS D KLAASSEN
-
依托单位:
REGULATION OF HEPATIC UPTAKE OF DRUGS AND XENOBIOTICS
-
批准号:6382269
-
项目类别:
-
资助金额:$30.0万
-
财政年份:2000
-
负责人:CURTIS D KLAASSEN
-
依托单位:
REGULATION OF BILIARY EXCRETION OF XENOBIOTICS BY MRP2
-
批准号:6751245
-
项目类别:
-
资助金额:$30.0万
-
财政年份:2000
-
负责人:CURTIS D KLAASSEN
-
依托单位:
REGULATION OF HEPATIC UPTAKE OF DRUGS AND XENOBIOTICS
-
批准号:6195877
-
项目类别:
-
资助金额:$35.25万
-
财政年份:2000
-
负责人:CURTIS D KLAASSEN
-
依托单位:
REGULATION OF BILIARY EXCRETION OF XENOBIOTICS BY MRP2
-
批准号:6127403
-
项目类别:
-
资助金额:$30.0万
-
财政年份:2000
-
负责人:CURTIS D KLAASSEN
-
依托单位:
Regulation of Hepatic Excretion of Xenobiotics by Mrps
-
批准号:7274868
-
项目类别:
-
资助金额:$33.9万
-
财政年份:2000
-
负责人:CURTIS D KLAASSEN
-
依托单位:
REGULATION OF HEPATIC UPTAKE OF DRUGS AND XENOBIOTICS
-
批准号:6642193
-
项目类别:
-
资助金额:$30.0万
-
财政年份:2000
-
负责人:CURTIS D KLAASSEN
-
依托单位:
Regulation of Hepatic Uptake of Drugs and Xenobiotics
-
批准号:7126389
-
项目类别:
-
资助金额:$35.89万
-
财政年份:2000
-
负责人:CURTIS D KLAASSEN
-
依托单位:
REGULATION OF HEPATIC UPTAKE OF DRUGS AND XENOBIOTICS
-
批准号:6525264
-
项目类别:
-
资助金额:$30.0万
-
财政年份:2000
-
负责人:CURTIS D KLAASSEN
-
依托单位:
Regulation of Hepatic Uptake of Drugs and Xenobiotics
-
批准号:7283661
-
项目类别:
-
资助金额:$34.85万
-
财政年份:2000
-
负责人:CURTIS D KLAASSEN
-
依托单位:
REGULATION OF BILIARY EXCRETION OF XENOBIOTICS BY MRP2
-
批准号:6382277
-
项目类别:
-
资助金额:$30.0万
-
财政年份:2000
-
负责人:CURTIS D KLAASSEN
-
依托单位:
Environmental Hormones: Effects on Thyroid Function
-
批准号:6914996
-
项目类别:
-
资助金额:$37.5万
-
财政年份:1998
-
负责人:CURTIS D KLAASSEN
-
依托单位:
海外基金